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Bronchodilator Response in Patients with Persistent
Allergic Asthma Could Not Predict Airway
Hyperresponsiveness
Bojana B. Petanjek, MD, Sanja P. Grle, MD, Dubravka Pelicaric´, MD, and Dubravka Vrankovic´, MD
Anticholinergics, or specific antimuscarinic agents, by inhibition of muscarinic receptors cause bronchodilatation, which might
correlate with activation of these receptors by the muscarinic agonist methacholine. The aim of this study was to determine whether
a positive bronchodilator response to the anticholinergic ipratropium bromide could predict airway hyperresponsiveness in patients
with persistent allergic asthma. The study comprised 40 patients with mild and moderate persistent allergic asthma. Diagnosis was
established by clinical and functional follow-up (skin-prick test, spirometry, bronchodilator tests with salbutamol and ipratropium
bromide, and methacholine challenge testing). The bronchodilator response was positive to both bronchodilator drugs in all
patients. After salbutamol inhalation, forced expiratory volume in 1 second (FEV1) increased by 18.39 6 6.18%, p , .01, whereas after
ipratropium bromide, FEV1 increased by 19.14 6 6.74%, p , .01. The mean value of FEV1 decreased by 25.75 6 5.16%, p , .01 after
methacholine (PC20 FEV1 [provocative concentration of methacholine that results in a 20% fall in FEV1] from 0.026 to 1.914 mg/mL).
Using linear regression, between methacholine challenge testing and bronchodilator response to salbutamol, a positive, weak, and
stastistically significant correlation for FEV1 was found (p , .05). Correlations between methacholine challenge testing and the
bronchodilator response to ipratropium bromide were positive and weak but not statistically significant. The positive bronchodilator
response to ipratropium bromide could not predict airway hyperresponsiveness.
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A irway hyperresponsiveness in asthma is characterizedby an increased sensitivity and an increased maximal
response to a variety of bronchoconstrictor agents.1–4 It is
known that inflammatory processes have been associated
with the presence of airway hyperresponsiveness in
subjects with asthma.5,6 Airway hyperresponsiveness can
be quantified by measuring the dose or concentration of
inhaled methacholine or histamine that causes a 20%
decrease in forced expiratory volume in 1 second (FEV1)
(PC20FEV1 [provocative concentration of methacholine
that results in a 20% fall in FEV1]).
Neural mechanisms have long been regarded as factors
contributing to the pathogenesis of asthma and involved in
airway hyperresponsivenes, a hallmark of asthma.7
Cholinergic nerves play an important role in the regulation
of airway calibre in many species, including humans, and
they form the dominant constrictor mechanism in the
airways. Preganglionic and postganglionic parasympathetic
nerves release acethylcholine. Anticholinergics, or mus-
carinic antagonists, by inhibition of muscarinic receptors
cause bronchodilatation, which might correlate with
activation of these receptors by the muscarinic agonist
methacholine.
Bronchodilator responsiveness and bronchoconstrictor
responsiveness have been considered physiologic opposites
in patients with obstructive airway disease. The study by
Douma and colleagues suggested that bronchoconstrictor
responsiveness and bronchodilator responsiveness are not
highly correlated.8
We hypothesized whether the bronchodilator response
to anticholinergic ipratropium bromide correlates better
with methacholine challenge testing than the bronchodi-
lator response to the b2 agonist salbutamol in patients with
persistent allergic asthma. If this is true, it would mean
that a positive bronchodilator response to ipratropium
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bromide could predict a positive bronchoconstrictor
response to methacholine in patients with persistent
allergic asthma. If so, another diagnostic tool for asthma
could be established that is simpler and cheaper, and thus
more widely acceptable, than the procedure for methacho-
line challenge testing.
Today, we are aware of a certain number of asthmatic
patients who do not have a positive bronchodilator
response to short-acting b2 agonists, such as salbutamol,
perhaps even 20% of them, owing to a b2 agonist receptor
gene polymorphism. In this light, an alternative measure of
airway response, besides the bronchodilatator test with a
short-acting b2 agonist, seems more important. Because
methacholine challenge testing is a costly and time-
consuming procedure, and the safety of both patients
and technicians should be considered in the design of the
test room and the test procedures, we hypothesized that
another diagnostic test, a bronchodilatator test with an
anticholinergic agent, could replace it concerning the
possibility of increased airway sensitivity detection as a
hallmark of asthma. To test this hypothesis, we decided to
perform serial lung function testing with different agents
on subjects with persistent allergic asthma with the
purpose of finding the best correlation between them.
The simplicity and safety of the bronchodilator test with
ipratropium bromide versus a methacholine challenge
warrants this evaluation.
Patients and Methods
The study was performed at the Outpatient Centre for
Diseases of the Respiratory System in Zagreb. The Ethics
Committee approved the study.
The study comprised 40 patients with persistent allergic
asthma, 23 males and 17 females, aged 16 to 65 years (34.40
6 14.16). A diagnosis of asthma was established according to
The Global Initiative on Asthma (GINA) classification9: 34
patients had GINA II, mild persistent asthma (peak
expiratory flow (PEF) or FEV1 $ 80% of predicted,
variability 20–30%), and 6 patients had GINA III, moderate
persistent asthma (PEF or FEV1 $ 70% of predicted).
None of the patients had used inhaled or oral
corticosteroids, long-acting bronchodilators, theophyl-
lines, antihistamines, sodium cromoglycate, or nedocromil
sodium for at least 4 weeks preceding the study. Short-
acting bronchodilators were not used for at least 12 hours
before pulmonary function testing. Current or ex-smokers,
pregnant women, and patients with cardiovascular disease,
rhinosinusitis, or respiratory tract infections during the 4
weeks before the study were excluded.
Patients with inclusion criteria were recruited into the
study one after another by the time of arrival at the
outpatient centre during 2 autumn months.
Each patient underwent pulmonary function testing
(spirometry, bronchodilator tests with salbutamol and
ipratropium bromide), methacholine challenge testing,
and the skin-prick test.
Skin-prick tests were performed with standard airborne
allergens10,11: house dust mite (Dermatophagoides ptero-
nyssinus), feathers, mould, dog and cat epithelium, mixed
tree pollen, mixed grass pollen, and mixed weed pollen. A
mean wheal diameter $ 3 mm of control solution was
considered positive.
A Pneumo Screen spirometer (Jaeger, Germany) was
used for pulmonary function tests. The observed para-
meters were the FEV1 and the forced vital capacity (FVC).
Forced expiratory manoeuvres were repeated until three
measurements of FEV1 reproducible to 100 mL were
obtained; the larger FEV1 value was used in analysis.
Reference values are those of the European Community for
Coal and Steel, CECA II.12
On the first day, spirometry with a bronchodilator test
with salbutamol was performed. After baseline spirometry,
subjects inhaled 400 mg of metered dose inhaler (MDI)
salbutamol (Ventolin, Pliva, Zagreb, Croatia). Spirometry
was repeated after 20 minutes.
On the second day, spirometry with an ipratropium
bromide test was performed. After baseline spirometry,
subjects inhaled 80 mg of MDI ipratropium bromide
(Atrovent, Boehringer Ingelheim, Ingelheim am Rhein,
Germany). Spirometry was repeated after 45 minutes.
A reversibility test was considered positive if there was
a 12% increase in FEV1 and/or FEV1 5 200 mL compared
with prebronchodilator FEV1 expressed as a percentage of
predicted value.13
On the third day, methacholine challenge testing was
performed by the standardized 2-minute tidal breath-
ing method14,15 using a Pneumo Screen spirometer and
Pari Provocation Test I. Without a bronchodilator, the
baseline FEV1 had to be more than 70% of the predicted
value.13,16 Doubling concentrations of methacholine
(acetyl-b-methacholine chloride, Janssen Pharmaceutics,
Belgium) ranging between 0.03 and 8 mg/mL were given
by inhalation at intervals of 5 minutes, each for a period
of 2 minutes, after the first inhalation of normal
saline. FEV1 was measured after each inhalation. If
methacholine did induce a drop of 20% or more, the
intrapolated concentration at which a 20% drop in
FEV1 had occurred was calculated and termed the
PC20FEV1.
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Statistical analysis of the data was performed by using a
paired t-test. The results are expressed as mean 6 SD.
Methacholine PC20 was calculated from the log concentra-
tion-response curves by linear interpolation of the two
adjacent data points. All PC20 values were log-transformed
before analysis. Analyses were performed using linear
regression for correlations between the log-transformed
PC20 values and both bronchodilator test values.
Results
Forty patients with persistent allergic asthma were
included in the study. In all patients, the skin-prick test
was positive. Dermatophagoides pteronyssinus was the most
positive single allergen (37 of 40).
Table 1 shows the baseline characteristics of patients
with persistent allergic asthma (age, gender, baseline FEV1
and FVC, and atopic status).
Our results showed a positive bronchodilator response
to salbutamol in all patients with persistent allergic
asthma. After salbutamol inhalation, the mean value of
FEV1 increased by 18.39 6 6.18% (from 12.40 to 35.60%).
The mean value of FVC increased by 7.96 6 6.96% Both
spirometric values (FEV1 and FVC) were significantly
higher after the bronchodilator test (p , .01).
The bronchodilator response to ipratropium bromide
was also positive in all patients with persistent allergic
asthma. The mean value of FEV1 increased by 19.14 6
6.74% (from 12.10 to 37.20%). The mean value of FVC
increased by 8.74 6 6.98%. Spirometric values for FVC
and FEV1 were significantly higher after ipratropium
bromide inhalation (p , .01).
All patients with persistent allergic asthma had positive
methacholine challenge testing. The mean value of FEV1
decreased by 25.75 6 5.16% (from 20.20 to 40.40%) after
inhalation concentrations between 0.03 and 2.0 mg/mL of
methacholine (PC20FEV1 from 0.026 to 1.914 mg/mL).
Spirometric parameters were significantly lower (p , .01)
after methacholine challenge testing.
Table 2 shows the percentage of increase for parameter
FEV1 after the bronchodilator test with salbutamol and
ipratropium bromide and PC20FEV1 after methacholine
challenge testing.
Correlations between methacholine challenge testing
and bronchodilator response to salbutamol and ipratro-
pium bromide for FVC were positive, weak, and
statistically not significant. The correlation between
methacholine challenge testing and the bronchodilator
response to salbutamol for FEV1 was positive, weak, and
statistically significant (p , .05). The correlation between
methacholine challenge testing and the bronchodilator
response to ipratropium bromide for FEV1 was positive,
very weak, and statistically not significant.
Figure 1 shows a scatterplot diagrams of the percent
change in FEV1 after inhalation of ipratropium bromide
versus the natural logarithm of PC20FEV1 for methacho-
line challenge (r 5 .169; p . .05) and in FEV1 after
inhalation of salbutamol versus the natural logarithm of
PC20FEV1 for methacholine challenge (r5 .314, p5 .049).
Discussion
This study has measured the acute bronchodilator effect of
an inhaled anticholinergic agent (ipratropium bromide) in
40 subjects with persistent allergic asthma to determine if a
positive bronchodilator response predicts the presence of
airway hyperresponsiveness. Methacholine chloride is a
synthetic derivate of acetylcholine, which is a parasympa-
thetic neurotransmitter that is very important for airway
smooth muscle tone. As anticholinergic agents (such as
ipratropium) act through the same neural pathway as
methacholine but in opposite directions, we were inter-
ested in whether there is a correlation between broncho-
constrictor and bronchodilator response in airways.
In our patients with allergic asthma, FEV1 increased by
18.39% after salbutamol inhalation, whereas after ipra-
tropium, FEV1 increased by 19.14%. Our results corre-
spond to the results of other authors who have proven
reversibility to bronchodilators in patients with
asthma.8,13,14 A positive bronchodilator response to
ipratropium bromide indicates that patients with persis-
tent allergic asthma have increased cholinergic tone.17
Change in FEV1 is the primary outcome measure for
methacholine challenge testing.18 All asthmatics had
positive methacholine challenge testing. After inhalation
concentrations between 0.03 and 2.0 mg/mL of methacho-
line (PC20FEV1 from 0.026 to 1.914 mg/mL), the mean
Table 1. Baseline Characteristics of Patients with Persistent
Allergic Asthma
Number 40
Age (yr) 34.40 (16–65)
Male/female 23/17
Baseline FEV1 % 94.75%
Baseline FVC % 110.61%
Sensitization to 1 allergen 47.5%
Sensitization to 2 to 5 allergens 52.5%
FEV15 forced expiratory volume in 1 second; FVC5 forced vital capacity.
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value of FEV1 decreased by 25.75% (from 20.20 to
40.40%).
In this study, the correlation between a pre- and a
postbronchodilator response to salbutamol and methacho-
line challenge testing for parameter FEV1 (p , .05) was
proven significant. There was no significant correlation
between the pre- and postbronchodilator response to
ipratropium bromide and methacholine challenge testing
for FEV1. Our main finding was that a positive bronch-
odilator response to ipratropium bromide did not predict
a positive methacholine hyperresponsiveness test.
The study by Douma and colleagues showed a lack of
correlation between bronchoconstrictor response and
bronchodilator response in a population-based study.8
Bronchoconstrictor responsiveness and bronchodilator
responsiveness are two different phenotypic markers that
are not interchangeable in epidemiologic studies. The
absence of bronchodilator responsiveness does not imply
the absence of bronchoconstrictor responsiveness, even in
individuals with airway obstruction.
It is not surprising that application of an anti-
cholinergic drug to predict methacholine-induced bronch-
oconstriction in this study has failed given the complexity
of chronic airway inflammation and remodelling in
asthma, even if the activity of allergy-related airway
inflammation is known.
In this study, responses to salbutamol are better
correlated with the methacholine response than responses
to ipratropium. Anticholinergic therapy may prevent only
the bronchoconstrictor component resulting from a
cholinergic reflex, not the direct effects of bronchocon-
strictor mediators, in contrast to b-adrenergic agonists,
which reverse bronchoconstriction irrespective of mechan-
ism because they are functional antagonists. Ipratropium
bromide is a non-selective anticholinergic drug because it
blocks not only M3 receptors but also the prejunctional M2
receptors.19 Inhibition of the M2 receptors leads to more
acetylcholine release during cholinergic nerve stimulation,
which may overcome postjunctional blockade. Thus, the
non-selective cholinergic antagonists may be less efficient
Figure 1. A, Scatterplot diagram of the percent change in forced expiratory volume in 1 second (FEV1) after inhalation of ipratropium bromide
versus the natural logarithm of PC20FEV1 (provocative concentration of methacholine that results in a 20% fall in FEV1) for methacholine
challenge (r 5 .169, p . .05). B, Scatterplot diagram of the percent change in FEV1 after inhalation of salbutamol versus the natural logarithm of
PC20FEV1 for methacholine challenge (r 5 .314, p 5 .049). Dashed lines represent the 95% confidence interval for linear regression.
Table 2. Percentage of Increase for Parameter FEV1 after the Bronchodilator Test with Salbutamol and Ipratropium Bromide and
PC20FEV1 after Methacholine Challenge Testing
Salbutamol % of Increase FEV1 Ipratropium % of Increase FEV1 PC20FEV1 mg/mL
Mean 18.39 19.14 0.645
SD 6.18 6.74 0.540
Minimum 12.40 12.10 0.026
Maximum 35.60 37.20 1.914
FEV1 5 forced expiratory volume in 1 second; PC20FEV1 5 provocative concentration of methacholine that results in a 20% fall in FEV1.
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than selective M3 receptor antagonists. Recent data show
that the long-acting muscarinic antagonist tiotropium
bromide could inhibit smooth muscle–specific myosin
expression, which also inhibits the increase in and
contractility of airway smooth muscle mass and remodel-
ling, and prevent airway hyperresponsiveness.20
The b2 agonists produce bronchodilatation by direct
stimulation of b2 receptors on airway smooth muscle,
leading to relaxation. But b2 adrenoceptors, through which
salbutamol acts, are desensitized in asthma, in part owing
to the inflammatory effect of cysteinyl leukotrienes.21 In
addition, there are over 100 different inflammatory
mediators that modulate airway smooth muscle tone in
humans. It is well known that mediators of allergic
reaction, such as cysteinyl leukotrienes and endothelin,
could increase bronchial muscle hypertrophy.22 It is also
known that salbutamol could prevent bronchoconstriction
owing to cysteinyl leukotrienes, whereas this is not the case
with anticholinergics.23 Salbutamol is a potent broncho-
dilator, but it could also inhibit cysteinyl leukotriene
synthesis by the airway cells.24
Asthma is a complex disorder with a different disease
pattern and a different response to therapy, depending on
the combination of asthma genotype and phenotype in
each patient. It is worth the effort to perform the study
with a larger number of asthma patients to determine what
happens in those asthmatics with a negative bronchodi-
lator response to salbutamol. Futher studies must
investigate if ipratropium bronchodilator testing results
in asthmatics with a negative salbutamol test (and
probably with a gene polymorphism for the b2 agonist
receptor) could produce more useful data concerning
asthma diagnosis, therapy benefit, and prognostic value.
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